Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared a post on LinkedIn:
“My favorite study from today at ESMO Breast: PREcoopERA (IBCSG 67-22).
A window-of-opportunity trial in premenopausal ER+/HER2- early breast cancer asking a clinically important question: is giredestrant alone sufficient, or do we still need ovarian suppression?
231 patients randomized to giredestrant alone, giredestrant + triptorelin, or anastrozole + triptorelin. Primary endpoint: Ki67 suppression at 4 weeks on re-biopsy.
The answer: giredestrant alone did not meet non-inferiority vs giredestrant + OS (-68% vs -80% Ki67 reduction).
Even a next-generation SERD needs ovarian suppression in premenopausal patients at this time.”
Other articles about Breast Cancer on OncoDaily.